AstraZeneca’s rare disease business Alexion returns to JCR Pharmaceuticals for another deal, this time for a pact worth up to $825 million for its adeno-associated virus capsids.
Alexion will use JCR’s capsids, dubbed JUST-AAVs, in ...
↧